Why Resin Chromatography Falls Short for Advanced Biologics

Biologics and advanced therapies have transformed modern medicine, offering treatments for conditions that were once untreatable. From monoclonal antibodies to gene therapies and mRNA-based vaccines, these complex molecules are driving innovation in healthcare. 

But as biologics become more sophisticated, the processes used to purify them must evolve too. Traditional resin-based chromatography, long considered the gold standard, is increasingly showing its limitations in meeting the demands of next-generation biologics.  

These limitations can lead to costly delays, scalability challenges, and operational headaches for biopharmaceutical manufacturers. 

The Growing Complexity of Biologics 

Biologics are not small, simple molecules — they’re large, structurally complex, and often sensitive to processing conditions. Advanced therapies like mRNA vaccines and gene therapies add another layer of complexity, requiring purification methods that can handle: 

• High molecular weight and size variability 

• Fragile structures that tend to degrade under harsh conditions 

• Large-scale production needs for global supply 

Traditional resin chromatography was designed decades ago for smaller, less complex molecules. Today, newer methods like membrane chromatography are better suited for these needs. 

Key Limitations of Resin Chromatography 

1. Slow Cycle Times 

Resin chromatography relies on packed columns and diffusion-based binding, which can be time-consuming. Large molecules move slowly through resin pores, leading to longer processing times. For manufacturers under pressure to scale up production quickly (like during vaccine rollouts) these delays can be costly. 

2. Scalability Challenges 

As demand for biologics grows, processes must scale efficiently. Resin columns are heavy, require significant infrastructure, and can be difficult to scale without compromising performance. This adds complexity and cost to manufacturing facilities. 

3. High Buffer Consumption 

Resin-based systems often require large volumes of buffer for equilibration, washing, and elution. This not only increases operating costs but also creates logistical challenges for supply chain management. 

4. Risk of Fouling and Pressure Drops 

Packed resin beds can suffer from fouling, especially when processing viscous or particulate-rich feed streams. This can lead to pressure drops, reduced flow rates, and inconsistent performance. 

Why These Limitations Matter 

For advanced therapies, speed and reliability are critical. Delays in purification can slow time-to-market, impacting patient access and revenue. Inefficient processes also drive up costs, making therapies less affordable. In short, resin chromatography’s limitations are more than technical — they can affect the entire value chain. 

The Industry Is Looking for Alternatives 

Recognizing these challenges, biopharmaceutical manufacturers are exploring new technologies that can deliver: 

• Faster cycle times 

• High binding capacity for large molecules 

• Simpler, more scalable operations 

• Reduced buffer consumption 

One solution gaining traction is membrane chromatography, which uses convective flow rather than diffusion, enabling rapid processing and high efficiency. Membrane chromatography is designed to meet the needs of modern biologics, offering a practical alternative to traditional resin systems. 

The membrane chromatography market has grown significantly in recent years and is projected to continue gaining traction. A Research and Markets report expects the market to grow to $959.42 million by 2032. 

Key Takeaways 

• Resin chromatography struggles with large, complex molecules due to slower cycle times and scalability limitations. 

• Advanced biologics require purification methods that are faster, more efficient, and easier to scale. 

• Membrane chromatography offers a promising alternative for next-generation therapies. 

Ready to learn more? 

Early adopters are seeing competitive advantages including faster production cycles, lower costs, and greater flexibility to scale with demand. Manufacturers are increasingly asking how to integrate membrane chromatography effectively into their processes rather than whether it fits. Purexa membrane chromatography solutions are already helping manufacturers transform their purification processes and capture market opportunities.  

Explore how Purexa™ products can help you.